What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.53%Above 5Y avg (1.49%)
Annual Rate
CNY 0.28Paid annual
Payout Ratio
82.9%Moderate
Payback Period
40.4 yr
Last Ex-Dividend
May 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.77BCNY
711.88M · vs all stocks (USD)
Updated Sep 22, 2026
Trailing P/E
32.74x
vs Medical Devices peers
Updated Sep 22, 2026
Revenue (TTM)
1.13BCNY
169.41M · vs all stocks (USD)
Updated Sep 22, 2026
Profit Margin
12.51%
vs Medical Devices peers
Updated Sep 22, 2026
Beta
0.3740x
vs all stocks
Updated Sep 22, 2026
52-Week Change
-19.99%
vs all stocks
Updated Sep 22, 2026
Market Capitalization
4.77BCNY
711.88M · vs all stocks (USD)
Updated Sep 22, 2026
Enterprise Value
3.71BCNY
553.97M · vs all stocks (USD)
Updated Sep 22, 2026
Trailing P/E
32.74x
vs Medical Devices peers
Updated Sep 22, 2026
Forward P/E
9.35x
vs Medical Devices peers
Updated Sep 22, 2026
Price to Sales (TTM)
4.20x
vs Medical Devices peers
Updated Sep 22, 2026
Price to Book (MRQ)
2.30x
vs Medical Devices peers
Updated Sep 22, 2026
Enterprise to Revenue
3.27x
vs Medical Devices peers
Updated Sep 22, 2026
Enterprise to EBITDA
19.45x
vs Medical Devices peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 17.79×.Updated Sep 22, 2026
Gross Margin
64.89%
vs Medical Devices peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 60.92%.Updated Sep 22, 2026
Profit Margin
12.51%
vs Medical Devices peers
Updated Sep 22, 2026
Operating Margin
14.50%
vs Medical Devices peers
Updated Sep 22, 2026
Return on Assets (TTM)
3.65%
vs Medical Devices peers
Updated Sep 22, 2026
Return on Equity (TTM)
6.51%
vs Medical Devices peers
Updated Sep 22, 2026
Revenue (TTM)
1.13BCNY
169.41M · vs all stocks (USD)
Updated Sep 22, 2026
Revenue per Share (TTM)
2.70CNYUpdated Sep 22, 2026
Quarterly Revenue Growth
17.80%
vs Medical Devices peers
Updated Sep 22, 2026
Gross Profit (TTM)
691.42MCNY
103.21M · vs all stocks (USD)
Updated Sep 22, 2026
EBITDA (TTM)
208.62MCNY
31.14M · vs all stocks (USD)
Updated Sep 22, 2026
Net Income (TTM)
141.92MCNY
21.18M · vs all stocks (USD)
Updated Sep 22, 2026
Quarterly Earnings Growth (YoY)
-31.10%
vs Medical Devices peers
Updated Sep 22, 2026
Operating Cash Flow (TTM)
273.62MCNY
40.84M · vs all stocks (USD)
Updated Sep 22, 2026
Levered Free Cash Flow (TTM)
108.12MCNY
16.14M · vs all stocks (USD)
Updated Sep 22, 2026
Trailing Annual Dividend Rate
0.2820CNYUpdated Sep 22, 2026
Trailing Annual Dividend Yield
2.53%
vs all stocks
Updated Sep 22, 2026
5-Year Average Dividend Yield
1.49%
vs all stocks
Updated Sep 22, 2026
Payout Ratio
82.94%
vs Medical Devices peers
Updated Sep 22, 2026
Minority Interest (Equity)
-7.05MCNYFY2025 · Dec 31, 2025
Revenue
1.04BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
381.85MCNYFY2025 · Dec 31, 2025
Gross Profit
655.98MCNYFY2025 · Dec 31, 2025
Operating Income
187.87MCNY
28.04M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
180.32MCNYFY2025 · Dec 31, 2025
Income Tax Expense
1.52MCNYFY2025 · Dec 31, 2025
Net Income
178.80MCNYFY2025 · Dec 31, 2025
EBIT
181.66MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
249.38MCNYFY2025 · Dec 31, 2025
Research & Development
228.59MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
86.47MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
12.15MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
39.24MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
1.34MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.4300CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.4300CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
428.42MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
428.42MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
178.80MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
5.42MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
182.13MCNYFY2025 · Dec 31, 2025
Free Cash Flow
98.90MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
1.21BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
178.80MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
10.79MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
18.08MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-25.55MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-83.22MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-92.95MCNYFY2025 · Dec 31, 2025
Sale of Investments
97.60MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-134.39MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-212.96MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
545.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-748.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-120.83MCNYFY2025 · Dec 31, 2025
Other Financing Charges
4.65MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-319.19MCNYFY2025 · Dec 31, 2025
Shares Outstanding
428.49MSharesUpdated Sep 22, 2026
Float Shares
203.74MSharesUpdated Sep 22, 2026
% Held by Insiders
52.62%
vs all stocks
Updated Sep 22, 2026
% Held by Institutions
7.54%
vs all stocks
Updated Sep 22, 2026
Total Cash (MRQ)
1.31BCNY
195.50M · vs all stocks (USD)
Updated Sep 22, 2026
Total Cash per Share (MRQ)
3.06CNYUpdated Sep 22, 2026
Total Debt (MRQ)
261.96MCNY
39.10M · vs all stocks (USD)
Updated Sep 22, 2026
Total Debt to Equity (MRQ)
0.1267x
vs Medical Devices peers
Updated Sep 22, 2026
Current Ratio (MRQ)
3.11x
vs Medical Devices peers
Updated Sep 22, 2026
Book Value per Share (MRQ)
4.85CNYUpdated Sep 22, 2026
Total Assets
2.81BCNY
419.38M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.96BCNYFY2025 · Dec 31, 2025
Total Liabilities
700.79MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
852.08MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
4.28MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
696.51MCNYFY2025 · Dec 31, 2025
Cash
1.55BCNYFY2025 · Dec 31, 2025
Cash Equivalents
23.18MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.57BCNYFY2025 · Dec 31, 2025
Accounts Receivable
173.64MCNYFY2025 · Dec 31, 2025
Inventory
183.04MCNYFY2025 · Dec 31, 2025
Accounts Payable
133.47MCNYFY2025 · Dec 31, 2025
Short-term Debt
397.19MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
6.72MCNYFY2025 · Dec 31, 2025
Long-term Debt
841.79KCNYFY2025 · Dec 31, 2025
Common Stock (Book)
428.49MCNYFY2025 · Dec 31, 2025
Retained Earnings
929.52MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.11BCNY
314.77M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
9.36CNYUpdated Sep 22, 2026
52-Week High
14.88CNYUpdated Sep 22, 2026
52-Week Change
-19.99%
vs all stocks
Updated Sep 22, 2026
Beta
0.3740x
vs all stocks
Updated Sep 22, 2026
50-Day MA
11.00CNYUpdated Sep 22, 2026
200-Day MA
12.24CNYUpdated Sep 22, 2026
Avg 10-Day Volume
1.56MSharesUpdated Sep 22, 2026
Avg 30-Day Volume
1.85MSharesUpdated Sep 22, 2026
Diluted EPS (TTM)
0.3400CNYUpdated Sep 22, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.